PLAUR and breast carcinoma: Although further preclinical validation is required, and notwithstanding the existing limitations in toxicity assessment, the availability of human anti-uPAR targeting vehicles and their successful application as imaging agents firmly support the clinical translation of the present findings to determine the theranostic utility of uPAR in the management of aggressive tumors, such as prostate or breast cancers.